NeuroSense Therapeutics

NRSN

Market cap $25.1M

Upgrade to unlock

Positive

Neutral

Negative

Sentiment 3-Months

Positive

Neutral 100%

Negative

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial" CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional decline, reduced risk of ALS-related complications, and modulation of disease-relevant biomarkers CAMBRIDGE, Mass., March 16, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

CAMBRIDGE, Mass., Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

Strengthens Global IP Portfolio for PrimeC Through 2042 CAMBRIDGE, Mass., Feb. 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

Patent protection extended through 2043 Alzheimer's proof-of-concept study completed Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 21, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026 CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

CAMBRIDGE, Mass. , Dec. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

See News Rankings